Repligen RGEN
Nasdaq · Biological Products, (No Diagnostic Substances) · $9.2BData provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
1 story has a settled next close so far (1 on the Wire). The record starts speaking at three.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via DatabentoOperating leverage — margins
| Line Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $670.5M | $801.5M | $632.4M | $634.4M | $738.3M | +16.4% | +2.4% | |
| Cost of Revenue (COGS) | $279.3M | $345.8M | $353.9M | $359.8M | $352.0M | −2.2% | +6.0% | |
| Research & Development (R&D) | $34.3M | $43.9M | $42.7M | $43.2M | $54.2M | +25.4% | +12.1% | |
| Selling, General & Admin (SG&A) | $183.9M | $215.8M | $218.6M | $263.4M | $290.5M | +10.3% | +12.1% | |
| Operating Income (EBIT) | $167.2M | $224.7M | $47.7M | $-35.1M | $55.2M | +257.1% | −24.2% | |
| Interest Expense | $11.3M | $1.2M | $2.0M | $20.7M | $21.5M | +3.8% | +17.5% | |
| Income Tax Expense | $25.3M | $33.2M | $21.1M | $-1.5M | $13.5M | +986.9% | −14.5% | |
| GAAP Net Income | $128.3M | $186.0M | $35.6M | $-25.5M | $48.9M | +291.6% | −21.4% | |
| Diluted EPS | $2.24 | $3.24 | $0.63 | $-0.46 | $0.86 | +287.0% | −21.3% | |
| Diluted Shares | 57,264 | 57,455 | 56,377 | 55,937 | 56,561 | +1.1% | −0.3% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | $603.8M | $523.5M | $751.3M | $757.4M | $566.0M | −25.3% | −1.6% | |
| Inventory | $184.5M | $238.3M | $202.3M | $143.0M | $170.5M | +19.2% | −2.0% | |
| Total Current Assets | $931.7M | $998.1M | $1.1B | $1.1B | $1.1B | +6.7% | +5.1% | |
| Total Assets | $2.4B | $2.5B | $2.8B | $2.8B | $2.9B | +4.2% | +5.8% | |
| Total Current Liabilities | $375.3M | $404.2M | $164.9M | $126.8M | $135.8M | +7.1% | −22.4% | |
| Total Debt (Short + Long Term) | $555.6M | $555.6M | $555.6M | $525.6M | $542.2M | +3.2% | −0.6% | |
| Total Liabilities | $608.3M | $620.9M | $866.3M | $856.9M | $843.6M | −1.6% | +8.5% | |
| Stockholders' Equity | $1.8B | $1.9B | $2.0B | $2.0B | $2.1B | +6.8% | +4.7% | |
| Net Cash / (Net Debt) | $48.2M | $-32.1M | $195.7M | $231.8M | $23.8M | −89.7% | −16.2% | |
| Invested Capital | $1.7B | $1.9B | $1.8B | $1.7B | $2.1B | +19.6% | +5.2% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | $119.0M | $172.1M | $113.9M | $175.4M | $117.4M | −33.1% | −0.3% | |
| Depreciation & Amortization (D&A) | $38.4M | $51.0M | $68.6M | $69.7M | $78.7M | +13.0% | +19.6% | |
| Stock-Based Compensation (SBC) | $27.5M | $27.3M | $25.6M | $48.1M | $32.6M | −32.2% | +4.3% | |
| Capital Expenditures (CapEx) | $67.1M | $84.8M | $36.2M | $25.7M | $23.5M | −8.4% | −23.1% | |
| Free Cash Flow (FCF) | $51.9M | $87.2M | $77.7M | $149.7M | $93.9M | −37.3% | +16.0% | |
| True FCF (ex-SBC Owner Cash) | $24.4M | $59.9M | $52.1M | $101.6M | $61.3M | −39.7% | +25.9% | |
| Share Repurchases (Buybacks) | $0 | $0 | $14.4M | $0 | $0 | — | — | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.